Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.

O'Dwyer, Michael E

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. [electronic resource] - Blood Jan 2004 - 451-5 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

0006-4971

10.1182/blood-2003-02-0371 doi


Adult
Aged
Benzamides
Blood Cell Count
Dose-Response Relationship, Drug
Female
Humans
Imatinib Mesylate
Immunosuppressive Agents--therapeutic use
Interferons--therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Middle Aged
Piperazines--therapeutic use
Probability
Prognosis
Pyrimidines--therapeutic use
Recurrence
Treatment Failure